Peripheral T-lymphocyte subsets in patients treated with Rituximab-Chlorambucil combination therapy for indolent NHL.
Laszlo
D
D
Bassi
S
S
Andreola
G
G
Agazzi
A
A
Antoniotti
P
P
Balzano
R
R
Mancuso
P
P
Bertolini
F
F
Martinelli
G
G
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes; D002699:Chlorambucil / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007694:Killer Cells, Natural; D018655:Lymphocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab; D016176:T-Lymphocyte Subsets / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D002699:Chlorambucil; D000069283:Rituximab